BidaskClub downgraded shares of Momenta Pharmaceuticals (NASDAQ:MNTA) from a sell rating to a strong sell rating in a research report report published on Thursday.
A number of other research analysts have also weighed in on the company. Cantor Fitzgerald set a $24.00 target price on Momenta Pharmaceuticals and gave the stock a hold rating in a report on Monday, October 1st. ValuEngine lowered Momenta Pharmaceuticals from a strong-buy rating to a buy rating in a report on Tuesday, October 16th. Stifel Nicolaus reissued a buy rating and set a $40.00 target price on shares of Momenta Pharmaceuticals in a report on Wednesday, October 10th. Zacks Investment Research raised Momenta Pharmaceuticals from a strong sell rating to a hold rating in a report on Monday, October 8th. Finally, Piper Jaffray Companies initiated coverage on Momenta Pharmaceuticals in a report on Monday, November 5th. They set an overweight rating and a $35.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Momenta Pharmaceuticals presently has a consensus rating of Buy and an average target price of $27.00.
MNTA stock opened at $11.39 on Thursday. Momenta Pharmaceuticals has a 1-year low of $10.10 and a 1-year high of $32.20.
In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 4,374 shares of the company’s stock in a transaction on Monday, November 12th. The stock was sold at an average price of $13.50, for a total value of $59,049.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 8,136 shares of company stock worth $106,026. Insiders own 4.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of MNTA. RA Capital Management LLC acquired a new position in Momenta Pharmaceuticals in the 2nd quarter valued at $75,717,000. BlackRock Inc. grew its holdings in Momenta Pharmaceuticals by 8.6% in the 2nd quarter. BlackRock Inc. now owns 11,681,112 shares of the biotechnology company’s stock valued at $238,880,000 after buying an additional 925,524 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Momenta Pharmaceuticals by 18.0% in the 2nd quarter. Janus Henderson Group PLC now owns 2,208,986 shares of the biotechnology company’s stock valued at $45,174,000 after buying an additional 336,859 shares in the last quarter. Vanguard Group Inc grew its holdings in Momenta Pharmaceuticals by 3.8% in the 3rd quarter. Vanguard Group Inc now owns 7,597,950 shares of the biotechnology company’s stock valued at $199,827,000 after buying an additional 280,177 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Momenta Pharmaceuticals by 3.8% in the 3rd quarter. Vanguard Group Inc. now owns 7,597,950 shares of the biotechnology company’s stock valued at $199,827,000 after buying an additional 280,177 shares in the last quarter. 95.71% of the stock is currently owned by hedge funds and other institutional investors.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
See Also: What is the quiet period?
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.